SCHEMBL3225709

SCHEMBL3225709

NCCCC(N)c1nc2ccccc2[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.61
ALDH1A1 P00352 4/20 0.51
POLB P06746 2/20 0.51
IDO1 P14902 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.44
SCN10A Q9Y5Y9 2/20 0.44
KMT2A Q03164 2/20 0.43
MASP2 O00187 1/20 0.43
MEN1 O00255 1/20 0.43
NUDT1 P36639 1/20 0.43
AOC3 Q16853 1/20 0.43
MLKL Q8NB16 3/20 0.42
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 2/20 0.42
ABCB11 O95342 1/20 0.42
TP53 P04637 1/20 0.42
PKM P14618 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3221142 0.95 TAAR1 (0.60) TAAR1ALDH1A1POLBIDO1L3MBTL1
Hydrochloric Acid SCHEMBL5400129 0.94 TAAR1 (0.58) TAAR1ALDH1A1POLBIDO1L3MBTL1
Hydrochloric Acid SCHEMBL5845865 0.90 TAAR1 (0.65) TAAR1ALDH1A1POLBIDO1L3MBTL1
Trifluoroacetic Acid SCHEMBL5411341 0.87 TAAR1 (0.49) TAAR1ALDH1A1POLBIDO1KMT2A
SCHEMBL3523940 0.83 TAAR1 (0.69) TAAR1ALDH1A1POLBIDO1L3MBTL1
SCHEMBL14029834 0.83 TAAR1 (0.56) TAAR1ALDH1A1POLBIDO1L3MBTL1
SCHEMBL27735848 0.83 TAAR1 (0.68) TAAR1ALDH1A1POLBIDO1L3MBTL1
Hydrochloric Acid SCHEMBL5846488 0.82 TAAR1 (0.67) TAAR1ALDH1A1POLBIDO1L3MBTL1
SCHEMBL14005055 0.81 TAAR1 (0.54) TAAR1ALDH1A1POLBIDO1L3MBTL1
SCHEMBL27980611 0.79 TAAR1 (0.67) TAAR1ALDH1A1POLBIDO1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190040073-A1 NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF SCIFLUOR LIFE SCIENCES, INC. 2019-02-07 US disclosed
US-10118929-B2 Nonanoic and decanoic acid derivatives and uses thereof SCIFLUOR LIFE SCIENCES, INC. (US) 2018-11-06 US disclosed
US-20170313708-A1 NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF FELIQS CORPORATION (JP) 2017-11-02 US disclosed
US-20100048536-A1 Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands GENESTE HERVE 2010-02-25 US disclosed
US-20080221082-A1 Ligands of Integrin Receptors ABBOTT GMBH & CO. KG (DE) 2008-09-11 US disclosed
US-7105508-B1 Integrin receptors antagonists ABBOTT GMBH & CO. KG (DE) 2006-09-12 US disclosed
EP-1286673-B8 LIGANDS OF INTEGRIN RECEPTORS ABBOTT GMBH & CO KG (DE) 2005-07-20 EP disclosed
EP-1286673-B1 LIGANDS OF INTEGRIN RECEPTORS BASF AG (DE) 2005-05-25 EP disclosed
US-20040077638-A1 Novel integrin receptor antagonists BASF AKTIENGESELLCHAFT (DE) 2004-04-22 US disclosed
US-20040063934-A1 Integrin ligands ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2004-04-01 US disclosed
EP-1307443-A2 NOVEL SUBSTITUTED DIARYL AZEPINE DERIVATIVES AS INTEGRIN LIGANDS BASF AKTIENGESELLSCHAFT (DE) 2003-05-07 EP disclosed
EP-1289962-A1 INTEGRIN LIGANDS BASF AKTIENGESELLSCHAFT (DE) 2003-03-12 EP disclosed
EP-1286673-A2 LIGANDS OF INTEGRIN RECEPTORS Basf Aktiengesellschaft (DE) 2003-03-05 EP disclosed
WO-2002051810-A2 INTEGRIN RECEPTOR LIGANDS ABBOTT GMBH & CO. KG (DE) 2002-07-04 WO disclosed
WO-2002014320-A2 NOVEL SUBSTITUTED DIARYL AZEPINE DERIVATIVES AS INTEGRIN LIGANDS BASF AKTIENGESELLSCHAFT (DE) 2002-02-21 WO disclosed
WO-2001096312-A1 INTEGRIN LIGANDS BASF AKTIENGESELLSCHAFT (DE) 2001-12-20 WO disclosed
WO-2001093840-A2 LIGANDS OF INTEGRIN RECEPTORS BASF AG (DE) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048536-A1 Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands ITGB3, ITGAL, ITGB4 TAAR1 1085/4885ALDH1A1 1678/4885POLB 4840/4885
US-20040063934-A1 Integrin ligands ITGB3, ITGAV, ITGAL TAAR1 2773/4885ALDH1A1 2630/4885POLB 4577/4885
US-20040077638-A1 Novel integrin receptor antagonists ITGB3, ITGAV, ITGA2B TAAR1 2079/4885ALDH1A1 3214/4885POLB 4717/4885
US-20190040073-A1 NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF FFAR3, FFAR2, FFAR1 TAAR1 2878/4885ALDH1A1 1356/4885POLB 4074/4885
US-20080221082-A1 Ligands of Integrin Receptors ITGB3, ITGAV, ITGA2B TAAR1 2007/4885ALDH1A1 2222/4885POLB 4398/4885
US-10118929-B2 Nonanoic and decanoic acid derivatives and uses thereof FFAR3, FFAR2, FFAR1 TAAR1 2878/4885ALDH1A1 1356/4885POLB 4074/4885
US-20170313708-A1 NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF FFAR3, FFAR2, FFAR1 TAAR1 2878/4885ALDH1A1 1356/4885POLB 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.